Last hope? new combo targets myeloma that resists standard drugs
NCT ID NCT01053949
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested a combination of pomalidomide and dexamethasone in 84 patients with advanced multiple myeloma whose cancer had worsened despite treatment with bortezomib and lenalidomide. The goal was to see if this drug pair could shrink tumors and control the disease. Researchers also compared two different dosing schedules to find the safest and most effective approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pomalidomide and dexamethasone
What this could lead to
If successful, this could provide a new treatment option for multiple myeloma patients who have not responded to other therapies.
What could go wrong
This is a phase II trial with only 84 participants, so results may not apply broadly. The drug combination may cause side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU-Hôpital Sud, avenue Laennec,
Amiens, 80054, France
-
Hématologie Clinique, CHU, Hôpital d'Enfants
Dijon, 21000, France
-
Hématologie Clinique, Hôpital Robert Debré, CHU Reims
Reims, 51092, France
-
Hématologie, CHRU, Hôpital A.Michallon
Grenoble, 38043, France
-
Hématologie, CHRU, Hôpital Purpan
Toulouse, 31059, France
-
Hématologie, CHRU, Hôpitaux de Brabois
Nancy, 54511, France
-
Hématologie, CHU, avenue G.Clemenceau
Caen, 14033, France
-
Hématologie, Hôpital Avicenne
Bobigny, 93009, France
-
Hématologie, Institut Paoli Calmette
Marseille, 13273, France
-
Hôpital Edouard HERRIOT
Lyon, 69437, France
-
Hôpital PONTCHAILLOU, CHU de RENNES
Rennes, 35033, France
-
Maladies du Sang, CHRU, Hôtel Dieu
Nantes, 44035, France
-
Maladies du Sang, CHU - Hôpital St Antoine
Paris, 75571, France
-
Médecine Interne, CHRU, Hôpital Sud
Rennes, 35056, France
-
Onco-Hématologie, CHRU- Hôpital Bretonneau
Tours, 37044, France
-
Service Immuno-Hématologie, Hôpital Saint-Louis
Paris, 75475, France
-
Service d'Hématologie, Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Service des Maladies du Sang, CHRU
Lille, 59037, France
-
Service des Maladies du Sang, Hôpital Haut-Levèque
Pessac, 33604, France